Currently, the screening process for hundreds of thousands of compounds is a slow and laborious process and has not worked in cases where the natural ligand for the target is a large protein. Overall, present screening processes remain time consuming and the most costly part of the drug development process.
Process combines several, well-established methods to streamline drug discovery.
The Surrogates are then used to generate Site Directed Assays that allow the identification of small molecule leads through High Throughput Screening protocols. Process ensures that lead compounds interacting with the hotspot have the necessary attributes of effective pharmacophores for drug discovery. Process was developed by DGI's Founder, President and CEO, Arthur J. Blume, Ph.D. Prior to founding DGI, Dr. Blume held various senior positions at Lederle Laboratories and the Roche Institute of Molecular Biology. He has over 25 years of experience in basic research and drug discovery. Process combines well-established methods including recombinant antibody and peptide production, phage display, and in vitro biochemical assays into a single, universal drug discovery platform with distinct advantages over competing protocols.